Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy

Prostate

Volumn 76, Issue 8, 2016, Pages 703-714

  Akinboye, Emmanuel S ^a   Brennen, W Nathaniel ^a   Rosen, D Marc ^a   Bakare, Oladapo ^b   Denmeade, Samuel R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

dipeptidyl peptidase IV (DPPIV); emetine; fibroblast activation protein (FAP); linker; para aminobenzyloxycarbonyl (PABC); prodrug

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EMETINE; EMETINE DERIVATIVE; FIBROBLAST ACTIVATION PROTEIN; POLYPEPTIDE; PRODRUG; SERINE PROTEINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GELATINASE; MEMBRANE PROTEIN; SEPRASE;

ARTICLE; BREAST CANCER CELL LINE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY ASSAY; DERIVATIZATION; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LNCAP CELL LINE; MASS SPECTROMETRY; MCF 7 CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SOLID TUMOR; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIPEPTIDYL PEPTIDASE 4; DRUG DESIGN; EMETINE; GELATINASES; HUMANS; MALE; MEMBRANE PROTEINS; PRODRUGS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84959264167     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23162     Document Type: Article

References (43)

1. Wiegrebe W, Kramer WJ, Shamma M., The emetine alkaloids. J Nat Prod 1984; 47: 397-408.
2. Grollman AP., Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics. Proc Natl Acad Sci USA 1966; 56 (6): 1867-1874.
3. Jimenez A, Carrasco L, Vazquez D., Enzymic and nonenzymic translocation by yeast polysomes. Site of action of a number of inhibitors. Biochemistry 1977; 16 (21): 4727-4730.
4. Akinboye ES, Bakare O., Biological activities of emetine. Open Nat Prod J 2011; 4: 8-15.
5. Lambert AC, Toronto CM., The treatment of amoebic dysentery with emetine and bismuth iodide. Br Med J 1981; 1 (2978): 116-118.
6. Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N., Drug repositioning as a route to anti-malarial drug discovery: Preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J 2013; 12: 359.
7. Jondorf WR, Abbott BJ, Greenberg NA, Mead JAR., Anti-leukemic effectiveness of (-)-emetine and some of its derivatives. Pharmacologist 1970; 12: 282.
8. Panettiere F, Coltman CA., Phase I experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer 1971; 27 (4): 835-841.
9. Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ., A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer 1973; 31 (5): 1170-1175.
10. Siddiqui S, Firat D, Olshin S., Phase II study of emetine (NSC-33669) in the treatment of solid tumors. Cancer Chemother Rep 1973; 57: 423-428.
11. Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ., Treatment of advanced gastrointestinal cancer with emetine (NCS-33669). Cancer Chemother Rep 1974; 58: 229-232.
12. Kane RC, Cohen MH, Broder LE, Bull MI, Creaven PJ, Fossieck BE., Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma. Cancer Chemother Rep 1975; 59: 1171-1172.
13. Troconis M, Ma W, Nichols DE, McLaughlin J., Molecular modeling study of tubulosine and other related ipecac alkaloids. J Comput-Aided Mol Des 1998; 12 (5): 411-418.
14. Wong W, Bai XC, Brown A, Fernandez IS, Hanssen E, Condron M, Tan YH, Baum J, Scheres SH., Cryo-EM structure of the plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine. eLife 2014; 3: e03080.
15. Akinboye ES, Rosen DM, Denmeade SR, Kwabi-Addo B, Bakare O., Design, synthesis, and evaluation of ph-dependent hydrolyzable emetine analogs as treatment for prostate cancer. J Med Chem 2012; 55 (17): 7450-7459.
16. Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O., Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorg Med Chem 2015; 23 (17): 5839-5845.
17. Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, Wolf BB., Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 2006; 580 (6): 1581-1586.
18. Brennen WN, Isaacs JT, Denmeade SR., Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012; 11 (2): 257-266.
19. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ., Regulation and heterodimeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectoderma origin. Cancer Res 1993; 53 (14): 3327-3335.
20. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ., Cell-surface glycoproteins of human sarcomas: Differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci USA 1988; 85 (9): 3110-3114.
21. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E;, Rettig WJ, Gorrell MD., Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodeling interface in human cirrhosis. Hepatology 1999; 29 (6): 1768-1778.
22. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR,. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8 (9): 2912-2923.
23. Yu DMT, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrel MD., The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010; 277 (5): 1126-1144.
24. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ., Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274 (51): 36505-36512.
25. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR., Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008; 47 (3): 1076-1086.
26. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR., Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012; 104 (17): 1320-1334.
27. Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR., Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate 2014; 74 (13): 1308-1319.
28. LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR., Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther 2009; 8 (5): 1378-1386.
29. Denmeade SR, Jakobsen C, Janssen S, Khan SR, Lilja H, Christensen SB, Isaacs JT., Prostate-specific antigen (psa) activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95 (13): 990-1000.
30. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT., Engineering a prostate-specific membrane antigen- activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4 (140): 86.
31. Khan SR, Denmeade SR., In vivo activity of a psa-activated doxorubicin prodrug against psa-producing human prostate cancer xenografts. Prostate 2000; 45 (1): 80-83.
32. Carl PL, Chakravarty PK, Katzenellenbogen JA., A novel connector linkage applicable in prodrug design. J Med Chem 1981; 24 (5): 479-480.
33. Dubowchik GM, Firestone RA., Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 1998; 8 (23): 3341-3346.
34. Elsadek B, Graeser R, Warnecke A, Unger C, Saleem T, El-Melegy N, Madkor H, Kratz F., Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen. ACS Med Chem Lett 2010; 1 (5): 234-238.
35. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Reuter VE, Nanus DM., Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997; 33 (4): 225-232.
36. Vanhoof G, De Meester I, van Sande M, Scharpé S, Yaron A., Distribution of proline-specific aminopeptidases in human tissues and body fluids. Eur J Clin Chem Clin Biochem 1992; 30 (6): 333-338.
37. Wilson MJ, Ruhland AR, Quast BJ, Reddy PK, Ewing SL, Sinha AA., Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl 2000; 21 (2): 220-226.
38. Yaron A, Naider F., Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 1993; 28 (1): 31-81.
39. Buckley SJ, Collins PJ, O'Connor BF., The purification and characterization of novel dipeptidyl peptidase IV-like activity from bovine serum. Int J Biochem Cell Biol 2004; 36 (7): 1281-1296.
40. Garcia-Aparicio C, Bonache M, Meeseter I, San-Felix A, Balzarini J, Camarasa M, Velazquez S., Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach. J Med Chem 2006; 49 (17): 5339-5351.
41. Diez-Torrubia A, Cabrera S, Castro S, Garcia-Aparicio C, Mulder G, De Meester I, Camarasa M, Balzarini J., Novel water-soluble prodrugs of acyclovir cleavable by dipeptidyl peptidase IV (DPPIV/CD26). Eur J Med Chem 2013; 70: 456-468.
42. Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W, Wolf BB., Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 2006; 281 (11): 7437-7444.
43. Litvinov IV, Griend DJV, Xu Y, Antony L, Dalrymple SL, Isaacs JT., Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006; 66 (17): 8598-8607.